Klotho Neurosciences, Inc. (NASDAQ: KLTO) has announced a strategic partnership with AAVnerGene Inc., a biotech company based in Rockville, MD, known for its advanced AAV manufacturing and tissue-targeted delivery technologies. This collaboration aims to address challenges in AAV gene therapy, including high drug costs and dose-related toxicity, by leveraging AAVnerGene's proprietary platforms. The partnership will utilize the AAVone system to reduce manufacturing costs and the ATHENA platform for efficient tissue-targeted delivery. Klotho Neurosciences plans to apply these technologies to accelerate the development of its gene therapy candidates, such as KLTO-101 for Alzheimer's and Parkinson's diseases, KLTO-202 for ALS, and KLTO-303 for aging-related conditions. The collaboration is expected to result in more affordable and innovative treatments for both rare and common neurological diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.